JP2025516358A - テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 - Google Patents

テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 Download PDF

Info

Publication number
JP2025516358A
JP2025516358A JP2024565272A JP2024565272A JP2025516358A JP 2025516358 A JP2025516358 A JP 2025516358A JP 2024565272 A JP2024565272 A JP 2024565272A JP 2024565272 A JP2024565272 A JP 2024565272A JP 2025516358 A JP2025516358 A JP 2025516358A
Authority
JP
Japan
Prior art keywords
cancer
compound
formula
group
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024565272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516358A5 (enExample
Inventor
エヴァン ジェイ． ホーン
ジョシュア ディー． ハンセン
マシュー ディー． アレクサンダー
フェイ ホアン
マーク エー． ナジー
Original Assignee
ツリーライン バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツリーライン バイオサイエンシズ インコーポレイテッド filed Critical ツリーライン バイオサイエンシズ インコーポレイテッド
Publication of JP2025516358A publication Critical patent/JP2025516358A/ja
Publication of JP2025516358A5 publication Critical patent/JP2025516358A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024565272A 2022-05-06 2023-05-04 テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 Pending JP2025516358A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263339262P 2022-05-06 2022-05-06
US63/339,262 2022-05-06
US202263398769P 2022-08-17 2022-08-17
US63/398,769 2022-08-17
US202263429814P 2022-12-02 2022-12-02
US63/429,814 2022-12-02
US202363454477P 2023-03-24 2023-03-24
US63/454,477 2023-03-24
PCT/US2023/020987 WO2023215471A1 (en) 2022-05-06 2023-05-04 Tetrahydroisoquinoline heterobifunctional bcl-xl degraders

Publications (2)

Publication Number Publication Date
JP2025516358A true JP2025516358A (ja) 2025-05-27
JP2025516358A5 JP2025516358A5 (enExample) 2026-05-01

Family

ID=86760567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024565272A Pending JP2025516358A (ja) 2022-05-06 2023-05-04 テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤

Country Status (7)

Country Link
US (1) US20250282771A1 (enExample)
EP (1) EP4519260A1 (enExample)
JP (1) JP2025516358A (enExample)
AU (1) AU2023265886A1 (enExample)
CA (1) CA3256666A1 (enExample)
MX (1) MX2024013311A (enExample)
WO (1) WO2023215471A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260111020A (ko) * 2023-11-07 2026-07-14 트리라인 바이오사이언시스, 인크. 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제
AU2024378690A1 (en) * 2023-11-07 2026-05-07 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
IL327973A (en) * 2023-11-07 2026-06-01 Treeline Biosciences Inc Tetrahydroisoquinoline heterobifunctional bcl-xl degraders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
WO2020163823A2 (en) 2019-02-08 2020-08-13 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
AU2020310147A1 (en) 2019-07-10 2022-01-06 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
CN112707900B (zh) 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
CA3163593A1 (en) 2020-01-15 2021-07-22 Guangrong Zheng Therapeutic agents and methods of treatment
CA3173843A1 (en) 2020-04-28 2021-11-04 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
WO2023044046A1 (en) 2021-09-17 2023-03-23 Kymera Therapeutics, Inc. Bcl-xl degraders and uses thereof

Also Published As

Publication number Publication date
WO2023215471A1 (en) 2023-11-09
EP4519260A1 (en) 2025-03-12
MX2024013311A (es) 2025-02-10
US20250282771A1 (en) 2025-09-11
AU2023265886A1 (en) 2024-11-07
CA3256666A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
CA3110267A1 (en) Tropomyosin receptor kinase (trk) degradation compounds and methods of use
CN114867735A (zh) Ras抑制剂
IL296648A (en) Indazole-based compounds and related methods of use
CA3039912A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US20240238423A9 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
US20250282771A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
JP2025516359A (ja) テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤
JP2024500378A (ja) 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
KR20250021371A (ko) 삼환식 퀴놀론 bcl6 이작용성 분해제
CN122070285A (zh) Bcl6双官能降解剂
TW202415655A (zh) １，８—萘啶—２—酮異雙功能ｂｃｌ６降解劑
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
WO2025101588A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
CN121752565A (zh) 三环喹诺酮bcl6双官能降解剂
EP4536649A1 (en) Quinolone bcl6 bifunctional degraders
JP2024501658A (ja) 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
WO2026102147A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2025101575A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
HK40076319A (en) Ras inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260422

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260703

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260810